Watson plans OTC switch for EC
This article was originally published in The Tan Sheet
Executive Summary
A next-generation emergency contraceptive could switch to nonprescription status eventually, according to Watson Pharmaceuticals, which licensed ulipristal acetate from HRA Pharma Feb. 1. "Ultimately, I suspect in time we will try to get the product to go OTC, just like the Plan B product," said CEO Paul Bisaro. Bisaro, speaking at the CLSA/Asia USA Investor's Forum in San Francisco March 2, noted UPA demonstrated high effectiveness for five days after unprotected sex. UPA is marketed in Europe as ellaOne by HRA Pharma and is currently in the new drug application stage with FDA
|
A next-generation emergency contraceptive could switch to nonprescription status eventually, according to Watson Pharmaceuticals, which licensed ulipristal acetate from HRA Pharma Feb. 1. "Ultimately, I suspect in time we will try to get the product to go OTC, just like the Plan B product," said CEO Paul Bisaro. Bisaro, speaking at the CLSA/Asia USA Investor's Forum in San Francisco March 2, noted UPA demonstrated high effectiveness for five days after unprotected sex. UPA is marketed in Europe as ellaOne by HRA Pharma and is currently in the new drug application stage with FDA. |